Humanigen, Inc. Stock Price - HGEN

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Humanigen, Inc. (QB) HGEN OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.037 6.07% 0.647 0.647 0.595 0.595 0.61 16:08:03
Bid Price Ask Price Spread Spread % News
0.52 1.00 0.48 48.0% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5 2,109 $ 0.59758 $ 1,260 2,060 0.50 - 1.544
Last Trade Time Type Quantity Stock Price Currency
13:51:40 100 $ 0.647 USD

Humanigen, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 72.97M 112.78M $ -12.00M - - 42.63M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
7.33k $ - 0.00% - -

more financials information »

Humanigen, Inc. News

Loading Messages....

Latest HGEN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HGEN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.700.8820.5620.65914474,284-0.053-7.57%
1 Month0.720.8820.5620.68937412,539-0.073-10.14%
3 Months0.831.050.5620.84197343,394-0.183-22.05%
6 Months1.061.500.5621.014,027-0.413-38.96%
1 Year0.59991.5440.501.116,8290.04717.85%
3 Years2.734.750.1251.2913,372-2.08-76.3%
5 Years3.9918.260.1252.5715,711-3.34-83.78%

Humanigen, Inc. Description

Humanigen is developing its portfolio of next-generation cell and gene therapies for the treatment of cancers. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring prevention of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.